9 Mar

Medtronic Launches Its Resolute Onyx 2.0 mm DES

WRITTEN BY Sarah Collins

Resolute Onyx 2.0 mm DES launch announcement

On February 26, 2018, Medtronic (MDT) announced that the FDA has approved the launch of its Resolute Onyx 2.0 mm (millimeter) DES (drug-eluting stent) in the United States. It is the smallest DES available in the market. Medtronic launched its Resolute Onyx 4.5 mm and 5 mm in May 2017.

Medtronic Launches Its Resolute Onyx 2.0 mm DES

Boston Scientific’s (BSX) Synergy stent is the market leader in the DES category. The company also offers Eluvia DES stents. Abbott Laboratories (ABT) offers Xience DES stents.

Features and benefits

The Resolute Onyx 2.0 mm DES is intended to provide treatment for people suffering from CAD (coronary artery diseases) who need to undergo a PCI (percutaneous coronary intervention) procedure but the larger stent technologies can’t be used due to smaller vessels in the person’s body. According to estimates, 65% of these smaller vessel cases are found to have lesions in critical heart locations.

According to Dave Moeller, vice president and general manager of Medtronic’s Coronary and Renal Denervation business, Cardiac and Vascular Group, “Furthering our core objective of developing technologies that address unmet patient needs, the introduction of the Resolute Onyx 2.0 mm DES allows physicians to expand treatment options for patients with smaller vessels. The Resolute Onyx DES is an incredibly deliverable product that incorporates various design enhancements enabling physicians to optimize treatment for a wide range of patients.”

Study details

Approval of the Resolute Onyx 2.0 mm was based on a clinical study, the results of which were presented at the EuroPCR 2017 annual meeting. The study results showed that the device met its predetermined performance goals. The results showed low target lesion failure, which came in at 5%, and low target lesion revascularization, which came in at 2%. The results of the clinical study showed no episodes of stent thrombosis and no incidences of cardiac death at 12 months.

Medtronic’s Resolute Onyx DES is available in the United States as well as in Europe in all sizes.

Latest articles

On June 25, AbbVie (ABBV) announced that it plans to buy Allergan (AGN) for ~$63 billion. At 10:20 AM ET, Allergan stock rose 27%, while AbbVie stock fell 15%.

On June 25, Credit Suisse initiated its coverage on Shake Shack with an “outperform” rating and a target price of $77—an upside potential of 15.4% from its closing price of $66.72 on June 24.

On June 25, the soft economic data isn't an isolated case. We have been getting a flurry of dismal data points. The US economy added only 75,000 non-farm jobs in May.

French retail giant Carrefour has agreed to sell an 80% stake in its China operations for ~$705 million to Suning.com, an Alibaba (BABA) backed company. While China represents a massive opportunity with its almost 1.4 billion population, it has not been an easy market for foreign companies, at least when it comes to retail and e-commerce.

On June 25, US Secretary of Agriculture Sonny Perdue told CNN in an interview that the US-China trade war has impacted US farmers. He said that farmers “are one of the casualties” of the trade war.

25 Jun

Hang Seng and Nikkei 225 Lose amid Trade Worries

WRITTEN BY Mayur Sontakke, CFA, FRM

After rising marginally yesterday, Hong Kong’s Hang Seng Index fell today. The index lost 1.15% to end at 28,185.98. Only seven stocks in the index rose, while 39 declined. Four remained unchanged. Tencent Holdings (TCEHY) was one of the worst performers with a 1.8% fall.

172.31.38.64